×
About 2,360 results

ALLMedicine™ CAR T-cell Therapy Center

Research & Reviews  799 results

The targeting effect of cetuximab combined with PD-L1 blockade against EGFR-expressing ...
https://doi.org/10.1080/07357907.2021.1894570
Cancer Investigation; Li Y, Gao Q et. al.

Mar 1st, 2021 - The switchable CARs have shown many advantages in CAR T-cell therapy. However, human primary T cells are required to evaluate of antigen-specific adaptors by IFN-γ assay or FACS analysis, which limits the throughput of adaptor screening. A sensiti...

Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Th...
https://doi.org/10.1182/blood.2020008865
Blood Strati P, Ahmed S et. al.

Feb 3rd, 2021 - Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may impact clinical efficacy. Here, we d...

Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cel...
https://doi.org/10.1002/ajh.26113
American Journal of Hematology; Nagle SJ, Murphree C et. al.

Feb 2nd, 2021 - Chimeric antigen receptor T-cell therapy (CAR T) is a novel intervention for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and other hematologic malignancies. However, it is associated with prolonged hematologic toxicity (PHT) that...

Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients.
https://doi.org/10.1182/blood.2020008759
Blood Mamlouk O, Nair R et. al.

Jan 29th, 2021 - Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients.|2021|Mamlouk O,Nair R,Iyer SP,Edwards A,Neelapu SS,|

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refra...
https://doi.org/10.1182/blood.2020009432
Blood Baird JH, Frank MJ et. al.

Jan 29th, 2021 - The prognosis for patients with large B-cell lymphoma (LBCL) progressing after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first three consecutive patients with autologous CAR19-re...

see more →

Guidelines  23 results

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 5th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

CAR T-cell therapy could ‘revolutionize’ treatment of advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{808d4883-a0e1-4574-b61d-ec5ce62aa752}/car-t-cell-therapy-could-revolutionize-treatment-of-advanced-multiple-myeloma

May 29th, 2020 - JNJ-4528, a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated th...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  1,155 results

The targeting effect of cetuximab combined with PD-L1 blockade against EGFR-expressing ...
https://doi.org/10.1080/07357907.2021.1894570
Cancer Investigation; Li Y, Gao Q et. al.

Mar 1st, 2021 - The switchable CARs have shown many advantages in CAR T-cell therapy. However, human primary T cells are required to evaluate of antigen-specific adaptors by IFN-γ assay or FACS analysis, which limits the throughput of adaptor screening. A sensiti...

Genome-Edited Donor-Derived Anti-CD19 CAR T-Cell Therapy Is Active in B-Cell Acute Lymphoblastic Leukemia
https://ascopost.com/issues/february-25-2021/genome-edited-donor-derived-anti-cd19-car-t-cell-therapy-is-active-in-b-cell-acute-lymphoblastic-leukemia/

Feb 24th, 2021 - Pooled results of two phase I studies, reported in The Lancet by Reuben Benjamin, MBBS, of the Department of Haematological Medicine, King’s College Hospital, London, and colleagues, indicate that the genome-edited donor-derived allogeneic anti-CD...

Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/overcoming-cd58-loss-may-be-promising-path-to-overcoming-resistance-to-car-t-cell-therapies/

Feb 24th, 2021 - Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell ther...

Early Research Explores Relationship Between CD58 Loss and Resistance to CAR T-Cell Therapies
https://www.ascopost.com/issues/february-10-2021/early-research-explores-relationship-between-cd58-loss-and-resistance-to-car-t-cell-therapies/

Feb 9th, 2021 - Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell ther...

Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Th...
https://doi.org/10.1182/blood.2020008865
Blood Strati P, Ahmed S et. al.

Feb 3rd, 2021 - Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may impact clinical efficacy. Here, we d...

see more →

News  381 results

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL
https://www.medscape.com/viewarticle/942375

Dec 9th, 2020 - Giving steroids to patients with relapsed/refractory high-grade B-cell non-Hodgkin's lymphoma (B-NHL) following chimeric antigen receptor (CAR) T-cell therapy may place them at substantially increased risk of infection, suggests a real-world analy...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
https://www.staging.medscape.com/viewarticle/939270

Oct 15th, 2020 - The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed...

see more →